树突状细胞介导的精准T细胞免疫疗法
癌症是全人类的第一大杀手，是影响人类健康及寿命的最大威胁。中国是世界上癌症死亡人数最多，肿瘤发病增长最快的国家。相关资料显示，2015年中国癌症发病人数为429万，其中恶性实体瘤发病率居高不下，同年，癌症死亡人数高达281万，因此研发更为有效的临床治疗手段显得尤为重要。
树突状细胞(DC)是免疫系统中功能最强大的抗原提呈细胞（APC），它通过自身膜表面MHC-Ⅰ类和MHC-Ⅱ类分子，将抗原呈递给T细胞以激活机体免疫功能。然而，树突状细胞在人体血液中含量极低，且长期的抗癌治疗导致树突状细胞活性降低，不能够介导充分且有效的T细胞免疫应答。我们发明的基于DC的精准免疫治疗技术正好可以解决上述问题。
我们的DC技术区别于目前常用的通过各种细胞因子刺激促使DC细胞短时间内有限增殖的特点，实现了树突状细胞大量培养；通过该技术培养的DC细胞在长期养过程中活性不发生改变；同时，该DC细胞易于进行工程化改造以针对不同的癌症，具有广泛的抗瘤谱；并且，DC不仅可以激活CTLs细胞，还可以活化NK细胞，使免疫治疗通过MHC限制性和非限制性的方式进行，有效预防肿瘤免疫逃逸，达到双倍治疗效果。
Dendrilife Cell-mediated Precise T-cell Immunotherapy
Cancer is among the worldwide leading causes of death, and poses a grave threat to people’s health and lives. Having the highest rate of tumor incidence, China possesses the highest number of cancer-related deaths worldwide. Statistics shows that, in 2015, there were 4.29 million cancer-related cases, among which the incidence of malignant tumors remained at a relatively high level. At the same time, cancer-related deaths reached 2.81 million. Therefore, in order to ease the situation, it’s important to develop more effective clinical treatment approaches.
Dendrilife cells (DCs) are the most powerful antigen pressing cells (APCs) that are in the immune system. With the MHC-I and MHC-II molecules on the surface of the cells, they allow antigen presentation to the T-cells and the activation of the immune functions. Yet, human blood contains an extremely limited number of DCs. Moreover, long-term cancer-fighting therapies will reduce the activity of DCs, in which case, they fail to comprehensively mediate an effective T-cell immune response. The self-developed DC-based precise immunotherapy can effectively solve this problem.
Different from the commonly used method that stimulates short-time DC proliferation with various cytokines, DC technology has achieved mass culture of DCs; the DC-based DCs can survive long-term in a culture without any activity reduction; meanwhile, DCs allow the engineering transformation to suit different cancers, representing an extensive anticancer spectrum. Furthermore, the DC technology is efficient in the activation of CTLs and NK cells, which enables both restrictive and non-restrictive immunotherapy, effectively preventing tumor immune escape and doubles the therapeutic efficacy. See the illustrations below:
DC技术治疗过程
DC Technology-based Treatment Process
